ArticleAlzheimer's & dementia (New York, N. Y.)
Developing educational materials to aid in Alzheimer's blood biomarker disclosure.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Short-term psychological impacts of Alzheimer's disease risk disclosure based on blood-biomarker results.Alzheimer's & dementia (New York, N. Y.)Article
- Developing educational materials to aid in Alzheimer's blood biomarker disclosure.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionA crucial step before clinical use of Alzheimer's disease (AD) blood biomarkers is the development of effective methods for disclosing results. This mixed-method study developed educational materials to disclose the dementia risk based on plasma phosphorylated tau (p-tau) results.
methodsParticipants diagnosed with mild cognitive impairment (MCI;
resultsParticipants rated the materials highly regarding value and comprehension. Thematic analysis revealed confusion about dementia progression and terminology. Participants preferred varied communication modes. Participants found utility in these materials but sought additional information on risk reduction. DISCUSSION: These findings highlight the utility of educational materials to aid in the disclosure of AD dementia risk based on plasma p-tau to individuals with MCI and their loved ones. Highlights: Individuals with mild cognitive impairment (MCI) find value in receiving blood biomarker results.Additional risk reduction information is helpful when communicating dementia risk.Individuals prefer medical information communicated visually.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.